1-8 of 8
Jordan Johnson
Close
Sort by
Journal Articles

Role of Mir-30e in Multiple Myeloma Cells Resistance to Lenalidomide and Bortezomib

Paola Neri, MD, PhD, Kathy Gratton, Li Ren, PhD, Jordan Johnson, Jiri Slaby, MD, Peter Duggan, MD, Douglas A. Stewart, MD, FRCP, Nizar J. Bahlis, MD
Journal: Blood
Blood (2012) 120 (21): 323.
https://doi.org/10.1182/blood.V120.21.323.323
Published: 2012
Journal Articles

Phase I Study of the PARP1-2 Inhibitor Veliparib in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma

Paola Neri, MD, PhD, Peter Duggan, MD, FRCPC, Kathy Gratton, Li Ren, PhD, Jordan Johnson, Jiri Slaby, MD, Douglas A. Stewart, MD, FRCP, Jonathan J Keats, PhD, Nizar J. Bahlis, MD
Journal: Blood
Blood (2012) 120 (21): 1862.
https://doi.org/10.1182/blood.V120.21.1862.1862
Published: 2012
Journal Articles

Lenalidomide Suppresses 5′-Cap-Independent C-MYC Translation in Multiple Myeloma Cells

Jiri Slaby, MD, Jordan Johnson, Paola Neri, MD, PhD, K Gratton, Li Ren, PhD, Douglas A. Stewart, MD, FRCP, Peter Duggan, MD, FRCPC, Nizar J. Bahlis, MD
Journal: Blood
Blood (2012) 120 (21): 3943.
https://doi.org/10.1182/blood.V120.21.3943.3943
Published: 2012
Journal Articles

High Cereblon Protein Expression Correlates with Improved Response and Survival in Myeloma Patients Treated with Lenalidomide

Alexander Klimowicz, PhD, Paola Neri, MD, PhD, Andrew Belch, MD, Michelle Dean, Li Ren, PhD, Kathy Gratton, Jiri Slaby, MD, Jordan Johnson, Peter Duggan, MD, FRCPC, Douglas A. Stewart, MD, FRCPC, Nizar J. Bahlis, MD
Journal: Blood
Blood (2012) 120 (21): 931.
https://doi.org/10.1182/blood.V120.21.931.931
Published: 2012
Journal Articles

Bortezomib-induced “BRCAness” sensitizes multiple myeloma cells to PARP inhibitors

Paola Neri, Li Ren, Kathy Gratton, Erin Stebner, Jordan Johnson, Alexander Klimowicz, Peter Duggan, Pierfrancesco Tassone, Adnan Mansoor, Douglas A. Stewart, Sagar Lonial, Lawrence H. Boise, Nizar J. Bahlis
Journal: Blood
Blood (2011) 118 (24): 6368–6379.
https://doi.org/10.1182/blood-2011-06-363911
Published: 2011
Includes: Supplemental data
Journal Articles

A miRNA Risk Score for the Prediction of Response to Lenalidomide in Multiple Myeloma (MM) Patients

Paola Neri, MD, PhD, Andrew R Belch, MD, Jordan Johnson, Kathy J Gratton, Li Ren, PhD, Peter Duggan, MD, FRCPC, Adnan Mansoor, MD, FCPS, FRCP(C), FCAP, Douglas A. Stewart, MD, FRCP, Nizar Bahlis, MD
Journal: Blood
Blood (2011) 118 (21): 987.
https://doi.org/10.1182/blood.V118.21.987.987
Published: 2011
Journal Articles

Mir-34a Sensitizes Multiple Myeloma (MM) Cells to the Proteasome Inhibitor Bortezomib

Erin Stebner, Paola Neri, MD, PhD, Jordan Johnson, Kathy J Gratton, Li Ren, PhD, Peter Duggan, MD, FRCPC, Douglas A. Stewart, MD, FRCP, Nizar Bahlis, MD
Journal: Blood
Blood (2011) 118 (21): 138.
https://doi.org/10.1182/blood.V118.21.138.138
Published: 2011
Journal Articles

Bortezomib Impairs Myeloma Cells (MM) Homologous Recombination Through Inhibition of the E2-Ubiquitin-Conjugating Enzyme UBC13

Paola Neri, MD, PhD, Li Ren, PhD, Jordan Johnson, Kathy J Gratton, Erin Stebner, Carolyn J Owen, MD, FRCPC, Peter Duggan, MD, FRCPC, Douglas A. Stewart, MD, FRCP, Nizar Bahlis, MD
Journal: Blood
Blood (2011) 118 (21): 1834.
https://doi.org/10.1182/blood.V118.21.1834.1834
Published: 2011